Water Tower Research Head of Business Development Tim Regan and Numinus Founder, Chair, and CEO Payton Nyquvest discuss the improving landscape in psychedelics. Payton shares how he felt energized and encouraged following the recent MAPS Psychedelic Science conference in Denver. Numinus is partnering with MAPS on MDMA clinical trials and Payton provides an update on their progress and explains how once approved MDMA may be integrated into their existing clinical infrastructure. Finally, we cover the widespread application of psychedelics and how they can help improve a range of mental health conditions.
